News Hub | News Direct

Poolbeg Pharma "really open" to different types of deal for POLB 001

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) VP of Business Development David English speaks to Proactive's Thomas Warner about the work he's doing to progress the clinical stage infectious disease pharmaceutical company's lead asset POLB 001. English says that Poolbeg is "in a good position" for partnering in general, adding that the company is "really open" to different types of deals for lead asset POLB 001. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 01, 2023 03:40 AM Eastern Standard Time

Video

Spectral MD releases final results for 2022

Spectral MD Holdings Ltd

Spectral MD Holdings Ltd (AIM:SMD) chief financial officer Nils Windler speaks to Proactive's Thomas Warner after releasing final results for 2022. Windler gives his take on the highlights from the year as well as the post-period and looks ahead to what investors can expect from the predictive analytics company in 2023. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

March 01, 2023 03:32 AM Eastern Standard Time

Video

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

Coya Therapeutics Inc.

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be held in-person and virtually from March 19 to March 22, 2023. The proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 12 consecutive months and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. The dual-mechanism investigational biologic combination combines low dose Interleukin-2 that is intended to enhance anti-inflammatory regulatory T cell function with a fusion protein that is intended to suppresses pro-inflammatory cell function and has been designed to be administered subcutaneously to minimize treatment burden for patients and caregivers. ALS is a disease of the parts of the nervous system that control voluntary muscle movement. In ALS, motor neurons (nerve cells that control muscle cells) are gradually lost. As these motor neurons are lost, the muscles they control become weak and then nonfunctional, thus leading to muscle weakness, disability, and eventually death. ALS is the most common form of motor neuron disease. The study was conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D. Dr. Appel is chair of Coya’s Scientific Advisory Board and is former chair of the Stanley H. Appel Department of Neurology. He is the director of the Ann Kimball & John W. Johnson Center for Cellular Therapeutics, Professor of Neurology at Weill Cornell Medical College, and the Peggy and Gary Edwards Distinguished Chair for the Treatment and Research of ALS at the Houston Methodist Research Institute. Presentation details are: Title: Novel Treg-modulating Immunotherapy Targets Inflammation in ALS. Date: Tuesday, March 21, 2023, at 11:00 am CST Conference: 2023 MDA Clinical & Scientific Conference ( https://www.mdaconference.org ) This article was originally published on Benzinga here. About Coya Therapeutics, Inc. Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

February 28, 2023 09:00 AM Eastern Standard Time

57% of Americans Can’t Cover A $1,000 Emergency With Savings—Here’s How You Can Prepare For Unexpected Costs And Build An Emergency Fund

DentalPlans.com

By Rachael Green, Benzinga According to the 2023 Bankrate survey, just 43% of Americans would be able to cover a $1,000 emergency expense with their savings. Even fewer would be able to cover their full living expenses for at least one month if they unexpectedly lost their primary source of income. For many, inflation and unemployment are the key factors preventing them from saving as much as they would like. But having an emergency fund is an important safety net to ensure that unexpected car repairs, medical emergencies, or job losses don’t completely derail your financial future. Here’s how to figure out how much you should have in your emergency fund and some other tips for protecting yourself and your family from financial hardship. Why Should You Have An Emergency Fund? No matter how much you earn, every household is bound to face an unexpected but unavoidable expense now and then. An emergency fund acts as a safety net so that when those emergencies happen, you can pay for them without going into debt or being forced to make tough financial decisions like tapping into your 401k or downsizing your lifestyle. Typically, the costs an emergency fund is supposed to cover include: Unemployment. Even if you have unemployment insurance, it doesn’t replace your full income. An emergency fund can help cover the gap while you look for another job. Urgent medical procedures Emergency home repairs, like a new roof or foundation repairs that you can’t afford to ignore. Unexpected car repairs Sudden death or disability How Much Should You Save In Your Emergency Fund? Common wisdom states that each household should have somewhere between three to six months’ worth of expenses set aside as an emergency fund. To calculate, you can include only your absolutely essential expenses for the month like rent, utilities, and groceries. If those essentials add up to $2,000 each month, then you should save $6,000 to $12,000 in an emergency fund. If that amount seems unattainable, set a more realistic goal for yourself to start because the bottom line is any emergency savings are better than nothing. Just keep adding what you can to it. Other Ways To Prepare For Emergencies In addition to setting money aside in an emergency fund, you can also better prepare yourself for emergencies by taking steps to either prevent them from happening in the first place or lowering the cost when they do. Here are some high-impact strategies for keeping your unexpected costs down: Keep Up With Home And Car Maintenance Putting off oil changes and ignoring your check engine light can end up costing you $8,000 or more in major engine repairs later and shorten your vehicle's lifespan by as much as 50,000 miles. Putting off annual home inspections and maintenance can lead to similarly hefty repair costs down the road. If you’re living paycheck to paycheck and avoiding these routine costs because you just don’t have the cash, there’s a lot you can learn to DIY, like oil changes and filter replacements. Join a Dental Savings Plan One of the biggest unplanned expenses people face is emergency dental work. According to the National Institute of Health, 90% of U.S. adults have some untreated decay in their teeth. But with 77 million Americans living without dental insurance and millions more with limited coverage that rarely covers the cost of even one major dental procedure, many put off treatment because it’s just too costly. With root canals costing anywhere between $1,000 and $4,350 and dentures as expensive as $28,000, even those with a healthy emergency fund can end up taking a huge hit if they need urgent dental care. Fortunately, there is a way to avoid draining your emergency fund or going into debt to take care of your teeth: a dental savings plan. Dental savings plans are membership programs that allow plan members to save 10% to 60% on virtually all dental procedures ranging from routine cleanings to more expensive treatments like root canals and dentures. Those steep discounts can turn an unexpected dental emergency into a much more affordable procedure. Plan members can also get similar discounts on preventative care to lower the risk of needing that more expensive work. Many plans even offer savings on cosmetic and restorative care that may not be covered by your dental insurance. No annual limits (save every time) and no restrictions based on health conditions. To get the discounted prices, you simply have to join a plan that includes the procedure you need and is accepted by a dentist near you. Then, show your membership card to that dentist, and you’ll be billed the lower rate. With over 140,000 dentists participating in a dental savings plan nationwide, it’s easy to find one in your area. On DentalPlans.com, for example, you can search a marketplace of thousands of dental savings plans and filter by location, procedure, or dentist to find one that meets your needs. You can also find plans that offer discounts on vision care and prescription medications to cut costs further. Consider Life Insurance And Disability Insurance In the case of sudden death or disability, even a 3-6-month emergency fund may not be enough to cover the lost income—especially after you factor in funeral expenses or, in the case of disability, the cost of medical care. A life insurance or disability insurance policy can protect your family from financial hardship in those worst-case scenarios. Visit DentalPlans.com for more information. Discount Health Program consumer & provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. This article was originally published on Benzinga here. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

February 28, 2023 09:00 AM Eastern Standard Time

AI Can Now Create Customizable Recipes – Here’s How A Robotic Food Automation Company Has Been Using AI To Become An Industry Leader

Blendid

By Faith Ashmore, Benzinga Interested in investing in Blendid’s campaign? Click here to get started! Artificial Intelligence (AI) technology is quickly proving to be a driver of innovation and efficiency and is fast becoming a normal part of life. In November 2022, tech and news outlet CNET started using AI to write financial articles. The articles were so well-written that the vast majority of the public didn’t realize until a tweet went viral. AI technology is rapidly expanding, and some companies like Blendid have looked to ensure they are ahead of the curve, having made early deployments of AI in their solutions. Whether for restaurant owners or at-home cooks, finding or creating the perfect recipe is a big undertaking. Not only do they have to craft a perfect blend of flavors, but they also have to figure out what they and their customers enjoy. Now imagine they are able to find the best recipes possible for their needs, but they didn’t have to do any of the hard work of producing them. Blendid is looking to revolutionize the game by doing just that, leveraging AI to produce better solutions. The company uses AI technology to create the most appealing recipes for its consumers. Blendid is a robotic and AI-enabled food automation solution company; it currently operates fully autonomous robotic kiosks for smoothies. By using consumer data from purchase behavior, ratings and reviews, and questionnaires, Blendid’s AI system is able to create the best recipes to put on a menu for a particular location. One of the company's best-selling drinks, Sunrise.ai, was crafted completely by AI! Blendid has even gone one step further and is developing a feature to use AI to create customized individual recipes. While this feature is currently only available at the lab, the company is seeing incredible feedback from test subjects and is looking forward to bringing it to the public in the near future. This feature could be especially groundbreaking because it will allow the robot-automated kiosks to create curated recipes for consumers that appeal to their taste preferences while taking into account any allergies and dietary restrictions. In the future, Blendid plans to align its AI-driven recipes with consumers’ personal microbiomes, satisfying both the gut and their taste palate. Blendid reports that its technology-driven model is performing extremely well. In combination with kiosks that can operate 24/7, consumers have access to healthy and personalized food around the clock while the company is able to maintain low operational costs and high margins. Blendid kiosks operate in universities, travel centers, retail stores, and hospitals across the country. The company most recently saw a 267% year-over-year revenue increase. Blendid is currently hosting a raise to expand its concept further. The company is currently working on expanding to a dozen additional geographies in the near future and has 500+ kiosks in contract. Previously, they raised more than $26 million. Interested in investing and being a part of their growth story? Click here to read more about Blendid’s raise and how to invest! This article was originally published on Benzinga here. Sunnyvale-based Blendid is revolutionizing the future of food service with its proprietary food automation platform (foodOS™), which efficiently and safely prepares and serves a range of healthy, fresh, and delicious food. A pioneer of the future of food service, Blendid's first concept in the market is an autonomous, contactless kiosk that uses robotics, machine vision, artificial intelligence, and healthy ingredients to create delicious smoothies that are customized to meet the unique health and dietary preferences of each consumer. Founded in 2015 by seasoned Silicon Valley entrepreneurs Vipin Jain, Venki Avalur, and Vijay Dodd, Blendid is improving the consumer experience by offering safe, cost-effective, and personalized food on-demand, while also reducing complexities and costs for the operators. Blendid has raised more $20M to date from a mix of venture and crowdfunding investors and is currently raising its Series B investment round. Visit www.startengine.com/blendid for more information and to invest in the future of food service automation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The preceding post was written and/or published as a collaboration between Benzingaâs in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuerâs securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17b disclosure linked in the campaign page for more information. Contact Details Erica Camilo 344130@email4pr.com Company Website http://www.blendid.com

February 28, 2023 09:00 AM Eastern Standard Time

News Release

What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?

RazorPitch DarioHealth

Dexcom and Dario think alike when it comes to the elements of an effective solution: user engagement, health outcomes, and return on investment. Diabetics are likely to have more than one chronic condition, Dario’s engaging and highly rated multi-chronic condition platform leads to better clinical outcomes and delivers a measurable ROI. Dario’s platform leapfrogs Dexcom’s mission (slide 24) “Where the company is going: Type 2 Non-Insulin, Pre-Diabetes, Patient Monitoring, and Health & Wellness”. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions. Market overlooking global industry leaders: Sanofi, Aetna, and now Dexcom validating DarioHealth’s revolutionization in healthcare management of people with single or multi-chronic conditions through a user-centric platform. DarioHealth is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. Dario’s user-centric platform offers people continuous and customized care for health, disrupting the traditional, doctor centric, episodic approach to healthcare. Dario’s platform empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and improved health outcomes which result in a measurable ROI to payors. Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions. On March 1, 2022, Dario entered a multi-year $30 million-dollar strategic agreement with Sanofi U.S.(EURONEXT: SAN and NASDAQ: SNY ) designed to accelerate commercial adoption and drive the expansion of digital health solutions on the Dario platform. Sanofi selected Dario to leverage its broad suite of digital therapeutics and its ability to engage patients for favorable clinical and financial outcomes, as the solution of choice for its U.S. commercial clients. Strategic partnerships with Sanofi, Virgin Pulse, Solera and Alliant give Dario access to more than 10,000 employers and more than 50 health plans as potential clients for the platform. Dario’s preliminary results demonstrate successful B2C to B2B transformation. Total revenue for the year is expected to be $27.5 million compared to $20.5 million in 2021. Higher revenues on lower spend demonstrates that the strategy of moving from B2C to B2B sales channels has resulted in an overall significant improvement in the financial profile of the Company. The Company reduced its operating loss by more than 30% compared to the third quarter ended September 30, 2022, and by more than 50% compared to the fourth quarter of 2021. DarioHealth had $49.3 million of cash and cash equivalents at the end of 2022. Dexcom’s global leadership position in CGM delivers solid results On February 9 th, 2023, Dexcom Reported 2022 Financial Results. Full year revenue grew 19% to $2.91 billion. GAAP operating income totaled $391.2 million or 13.4% of revenue. Dexcom delivered record new customer starts, drove multiple new product launches, and significantly expanded access to Dexcom CGM around the world. As of December 31, 2022, Dexcom held $2.46 billion in cash or equivalents. Sanofi delivers strong sales performance and double digit EPS growth On February 3 rd, 2023, Sanofi (EURONEXT: SAN and NASDAQ: SNY) reported full year 2022 results highlighting 7% sales growth to 43 Billion Euro and 17% EPS growth. Free cash flow from operations totaled 8.5 Billion Euro. Sanofi is an innovative global healthcare company chasing miracles of science to improve people’s lives. The Company provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, sustainably and socially responsible. RCA Financial Partners Inc. ("RCA Partners" or "we" is a consulting and advisory firm to small public and pre-IPO data resource innovators at the critical inflection point where proven technology requires prudent financing for success. We help our clients connect with well informed investors. To learn more about RCA Financial Partners and its data resource innovators, visit www.rcafinancialpartners.com. Disclaimers: This article contains sponsored content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. RazorPitch authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. RazorPitch has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website. This summary report was prepared by RCA Financial Partners and distributed by RazorPitch. RCA Financial Partners is not a securities broker-dealer, an investment adviser, or a bank, and, accordingly, this report is not subject to FINRA or SEC rules regarding broker-dealer securities research, nor to the regulations to which investment advisers or banks are subject, including regulations regarding independence of written communications. RCA has been retained and compensated by the subject company of this report. This report does not constitute, and should not be construed as an independent analysis of the subject company, or as an offer to buy or sell, or a solicitation of an offer to buy or sell any security. This report is published without regard to the specific needs of any person, and it does not take into account the particular financial situation or needs of any individual. Readers should seek professional financial advice, including tax advice, before taking any investment decision. This report is based on information that we believe to be reliable, but RCA Financial Partners does not make any express or implied representation or warranty as to the completeness, reliability, or accuracy of information contained in this report, or of information used to create this report. Further important disclosures and disclaimers are available at: www.rcafinancialpartners.com/about-us/legal-disclaimer/ Contact Details Mark McKelvie +1 585-301-7700 Company Website http://razorpitch.com

February 28, 2023 05:00 AM Eastern Standard Time

CleverTap’s Fintech Benchmark Report: Only 1 in 5 users that install fintech apps sign up within week one

CleverTap

CleverTap, the modern integrated retention cloud, released its Industry Benchmark Report for Fintech Apps 2022. As fintech apps continue to grow more popular, the number of players vying for market share has increased. This has subsequently reduced customer retention and “stickiness” for any one brand. Therefore, today more than ever, it is crucial that fintech companies find ways to drive customer “stickiness” by engaging users in effective ways that eventually drive transactions and fuel growth. The report reflects data collected from Asia-Pacific, Europe, India, Latin America, Middle-East, and North America. The report gives marketers a truly holistic view of key metrics within the fintech app landscape.It also spans a wide variety of fintech apps, including, but not limited to, mobile payment apps, cryptocurrency, and block chain services, along with banking and insurance among others. These insights will not only serve as a helpful starting point for developing successful engagement strategies, but also assist in understanding how an app fares in comparison to global averages. Some of the key metrics in the report include: Install to sign-up rate: Only 1 in 5 users that install fintech apps (21%) end up signing up within the first week. Average time to sign-up: 70% of the users that sign-up, do so within 75 seconds of launching the app for the first time. Sign-up to conversion rate: 95% of newly signed-up users make at least one financial transaction in the first month. Average time to convert: 76% of newly signed-up users move from onboarding to deeper-in-the-funnel engagement within an average of 7 days. Session frequency: On average, fintech app users launch their app around 11 times a month. Average repeat transaction rate for new users: 15% of newly signed-up users complete more than one transaction in the first week. Average click-through rate for push notifications: On average, 9% of Android users and 6% of iOS users will click on and interact with push notifications. Average click-through rate for in-app notifications: The click-through rate for in-app notifications is 24%, that’s about 3 times more than that of push notifications. Average email open rate: 34% users open emails sent by fintech companies Average Stickiness Quotient: Fintech apps enjoy a stickiness quotient of 22%, that indicates nearly one-quarter of MAUs consistently return to their fintech apps “The fintech industry has seen exponential growth in the last few years. Given the relentless competition within the space, fintech platforms need to step up their Omnichannel engagement efforts to better retain customers,” said Jacob Joseph, VP-Data Science, CleverTap. “The benchmark metrics laid out in our report provide a great starting point for growth marketers looking to develop effective marketing strategies. They will be able to compare numbers against global averages and pinpoint which aspects they are excelling at and which areas could use some attention or innovation.” 95% of new fintech users complete a monetary transaction in the first month. This shows that while users see value in fintech apps, it’s important to adopt customized user engagement strategies to boost retention on the platform. Today there is a real need for fintech brands to bake-in effective marketing strategies within their apps. Users will remain responsive as long as the experience is engaging and seamless. The benchmark report helps fintech apps understand how to build successful mobile communication campaigns, and also allows growth marketers to discover areas that require greater focus. The report can be downloaded here. About CleverTap CleverTap is the World's #1 Retention Cloud that helps app-first brands personalize and optimize all consumer touch points to improve user engagement, retention, and lifetime value. It's the only solution built to address the needs of retention and growth teams, with audience analytics, deep-segmentation, multi-channel engagement, product recommendations, and automation in one unified product. The platform is powered by TesseractDB™ - the world’s first purpose-built database for customer engagement, offering both speed and economies of scale. CleverTap is trusted by 2000 customers, including Gojek, Electronic Arts, TED, English Premier League, TD Bank, Carousell, AirAsia, Papa Johns, and Tesco. Backed by leading investors such as Sequoia India, Tiger Global, Accel, and CDPQ the company is headquartered in Mountain View, California, with presence in San Francisco, New York, São Paulo, Bogota, London, Amsterdam, Sofia, Dubai, Mumbai, Singapore, and Jakarta. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction. Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

February 27, 2023 02:51 PM Eastern Standard Time

News Release

Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing

Todos Medical Ltd.

Todos Medical CEO Gerald Commissiong joined Proactive's Natalie Stoberman to discuss the validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing. Commissiong also talked about how this new validation plan intertwines with this week's company update and the growth across Todos Medical's projects and subsidiary 3CL Pharma. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 27, 2023 01:15 PM Eastern Standard Time

Video

News Release

BioLargo subsidiary Clyra Medical Technologies adds medical industry veterans to board of directors

BioLargo Inc

BioLargo CEO Dennis Calvert joined Proactive's Natalie Stoberman to share more details of the addition of Nicholas Valeriani and Linda Park to the board of directors of subsidiary Clyra Medical Technologies. BioLargo noted that Valeriani has decades of executive experience in the medical device industry. He spent 34 years at Johnson & Johnson, where he led several corporate functions and was a member of its executive committee. Park is a trusted executive and legal professional with a proven track record of supporting and advising public companies at the corporate board and executive level at billion-dollar corporations. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 27, 2023 01:09 PM Eastern Standard Time

Video

Healthcare

Poolbeg Pharma "really open" to different types of deal for POLB 001

Spectral MD releases final results for 2022

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

57% of Americans Can’t Cover A $1,000 Emergency With Savings—Here’s How You Can Prepare For Unexpected Costs And Build An Emergency Fund

AI Can Now Create Customizable Recipes – Here’s How A Robotic Food Automation Company Has Been Using AI To Become An Industry Leader

What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?

CleverTap’s Fintech Benchmark Report: Only 1 in 5 users that install fintech apps sign up within week one

Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing

BioLargo subsidiary Clyra Medical Technologies adds medical industry veterans to board of directors